Prevalence and prognostic significance of extrarenal manifestations in patients with lupus nephritis: A retrospective cohort study
- 1Department of Rheumatology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- 2Information Medicine, Big Data Research Centre, Asan Medical Centre, Seoul, Republic of Korea.
Abstract
Objectives: To evaluate the prevalence and prognostic implications of extrarenal involvement in lupus nephritis (LN), with emphasis on treatment response and the risk of future renal and extrarenal flares. Methods: We retrospectively reviewed patients newly diagnosed with LN between January 2006 and December 2022 and categorized them according to the presence of extrarenal involvement at diagnosis. Renal response and remission at 12 months, defined according to the Definition of Remission in SLE (DORIS), as well as the incidence of renal and extrarenal flares during follow-up, were compared between groups. Factors associated with DORIS remission and renal response were assessed using multivariable logistic regression analyses. Results: Among 348 patients with LN, 156 (44.8%) had extrarenal involvement at diagnosis, most commonly hematological manifestations (59.0%). Rates of complete renal response (CRR) and DORIS remission at 12 months were comparable between patients with and without extrarenal involvement (CRR: 57.1% vs. 46.9%, p = 0.06; DORIS remission: 21.8% vs. 29.7%, p = 0.09). Over a median follow-up of 79.6 months, the incidence of renal flares (28.8% vs. 26.0%, p = 0.56) and extrarenal flares (26.3% vs. 24.5%, p = 0.74) did not differ significantly between groups. In multivariable analyses, baseline extrarenal involvement was not associated with DORIS remission (odds ratio [OR], 1.307; 95% confidence interval [CI]: 0.779–2.193; p = 0.310) or renal response (OR, 0.974; 95% CI: 0.564–1.682; p = 0.925). Conclusions: Extrarenal involvement is present in nearly half of patients at LN diagnosis, however, it does not appear to influence renal response, DORIS remission, or the long-term risk of renal or extrarenal flares.
Related
- Prevalence, timing and risk factors of extraintestinal manifestations in inflammatory bowel disease: a retrospective cohort study from a German tertiary referral center.
- Regulatory T cells in lung adenocarcinoma: Mechanisms of immune escape, prognostic significance and therapeutic opportunities (Review)
- Prognostic significance of KIF2C and its association with lactate metabolism in hepatocellular carcinoma
- Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study.
- One in Twenty: Prevalence and Outcomes of Patients Brought to EDs Under Québec's P-38 Mental Health Act—A Retrospective Cohort Study: Un patient sur vingt : prévalence et résultats chez les patients ayant été admis au service des urgences en vertu de la loi p-38 du Québec sur la santé mentale—Étude de cohorte rétrospective
BibTeX
@article{kim2026prevalence,
title = {{Prevalence and prognostic significance of extrarenal manifestations in patients with lupus nephritis: A retrospective cohort study}},
author = {Young-Eun Kim and Soo Min Ahn and Ji Seon Oh and Yong-Gil Kim and Chang-Keun Lee and Bin Yoo and Seokchan Hong},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0362170},
url = {https://doi.org/10.1371/journal.pone.0362170},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prevalence and prognostic significance of extrarenal manifestations in patients with lupus nephritis: A retrospective cohort study
AU - Young-Eun Kim
AU - Soo Min Ahn
AU - Ji Seon Oh
AU - Yong-Gil Kim
AU - Chang-Keun Lee
AU - Bin Yoo
AU - Seokchan Hong
PY - 2026
DA - 2026/11/10
JO - PLOS One
DO - 10.1371/journal.pone.0362170
UR - https://doi.org/10.1371/journal.pone.0362170
AB - Objectives: To evaluate the prevalence and prognostic implications of extrarenal involvement in lupus nephritis (LN), with emphasis on treatment response and the risk of future renal and extrarenal flares. Methods: We retrospectively reviewed patients newly diagnosed with LN between January 2006 and December 2022 and categorized them according to the presence of extrarenal involvement at diagnosis. Renal response and remission at 12 months, defined according to the Definition of Remission in SLE (DORIS), as well as the incidence of renal and extrarenal flares during follow-up, were compared between groups. Factors associated with DORIS remission and renal response were assessed using multivariable logistic regression analyses. Results: Among 348 patients with LN, 156 (44.8%) had extrarenal involvement at diagnosis, most commonly hematological manifestations (59.0%). Rates of complete renal response (CRR) and DORIS remission at 12 months were comparable between patients with and without extrarenal involvement (CRR: 57.1% vs. 46.9%, p = 0.06; DORIS remission: 21.8% vs. 29.7%, p = 0.09). Over a median follow-up of 79.6 months, the incidence of renal flares (28.8% vs. 26.0%, p = 0.56) and extrarenal flares (26.3% vs. 24.5%, p = 0.74) did not differ significantly between groups. In multivariable analyses, baseline extrarenal involvement was not associated with DORIS remission (odds ratio [OR], 1.307; 95% confidence interval [CI]: 0.779–2.193; p = 0.310) or renal response (OR, 0.974; 95% CI: 0.564–1.682; p = 0.925). Conclusions: Extrarenal involvement is present in nearly half of patients at LN diagnosis, however, it does not appear to influence renal response, DORIS remission, or the long-term risk of renal or extrarenal flares.
SN - 1932-6203
ER -